Related Experiment Video
Updated: Feb 24, 2026

Evaluation of a Reliable Biomarker in a Cecal Ligation and Puncture-Induced Mouse Model of Sepsis
Published on: December 9, 2022
Incremental value of novel immunonutritional-inflammatory markers over clinical models in predicting sepsis after
Hongmin Zhou1, Jun Luo2, Xiangcheng Zhan1
1Department of Urology, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai, 200072, China.
Background:
Sepsis is a serious complication after ureteroscopic lithotripsy (URSL), but its accurate pre-operative prediction remains difficult. This study aims to evaluate novel immunonutritional-inflammatory indices, which reflect the "nutrition-immunity-inflammation" axis, for predicting post-URSL sepsis.
Methods:
We conducted a retrospective cohort study of 569 patients undergoing URSL. Postoperative sepsis was diagnosed per Sepsis-3 criteria. A base clinical model was built using pre-operative variables from multivariate analysis. We then assessed the incremental predictive value of adding five indices (CALLY, PNI, CAR, NAR, NPAR) by evaluating discrimination (AUC), calibration, reclassification (NRI, IDI), and clinical utility (Decision Curve Analysis). A nomogram and web calculator were developed based on the CALLY-augmented model for clinical use.
Results:
Of 569 patients, 41 (7.2%) developed sepsis. The base model (including gender, platelet count, operation time, hydronephrosis, leukocyte esterase, and urine culture) had an AUC of 0.832. The CALLY index provided the most significant improvement, increasing the AUC to 0.918 (P = 0.007). The model with CALLY also showed superior reclassification (NRI = 0.404, IDI = 0.134; both P < 0.001) and significantly better fit (Likelihood Ratio Test P < 0.001). Decision curve analysis confirmed its greater net clinical benefit across practical risk thresholds.
Conclusion:
Immunonutritional-inflammatory indices, particularly the CALLY index, significantly improve the prediction of post-URSL sepsis over clinical factors alone. The developed tool enables personalized risk estimation, supporting precision medicine in perioperative care.
Trial Registration:
Chinese Clinical Trial Registry, ChiCTR2400092429. Registered 15 November 2024. Retrospectively registered.
Related Concept Videos
Acute Kidney Injury IV: Diagnostic Studies and Prevention
Acute Pyelonephritis II: Diagnostic Studies and Management
Urine Studies II: Urine Culture and Sensitivity Test
Urinary Tract Calculi II: Pathophysiology and Clinical Manifestations
Acute Kidney Injury III: Clinical Manifestations
Urinary Tract Calculi IV: Nutrition Therapy and Prevention

